ARK Invest Offloads $28.6M in Alphabet (GOOGL) Stock While Buying Meta (META) Shares

Table of Contents

Key Highlights

On September 9, 2026, ARK Invest offloaded 84,392 Alphabet shares valued at $28.6 million
The investment firm purchased 43,091 Meta Platforms shares worth $26.4 million following Meta’s Muse AI agent announcement
Meta’s stock price surged 6.55% while Alphabet dropped 2.28% on the same trading day
ARK expanded positions in biotech firms including Beam Therapeutics, CRISPR Therapeutics, and Intellia Therapeutics
The firm decreased its Tempus AI holdings by approximately $1.5 million

On Wednesday, September 9, 2026, Cathie Wood’s investment firm ARK Invest executed significant portfolio adjustments. The company divested 84,392 Alphabet shares valued at approximately $28.6 million through its ARKK and ARKW exchange-traded funds.

GOOGL Stock Card
Alphabet Inc., GOOGL

During the same trading session, ARK purchased 43,091 Meta Platforms shares totaling around $26.4 million. Meta’s stock climbed 6.55% following the company’s introduction of Muse, an innovative AI-powered agent designed to manage various tasks including e-commerce transactions, travel arrangements, and email management.

Mark Zuckerberg, Meta’s Chief Executive Officer, characterized this product as integral to the company’s vision of achieving “personal superintelligence.” The announcement provided shareholders with tangible evidence of Meta’s strategy for deploying its substantial AI investments.

Meta has projected capital expenditures ranging from $130 billion to $145 billion for the current year, with significant allocations directed toward artificial intelligence research and development.

Meanwhile, Alphabet’s stock declined 2.28% during the same period. Mizuho Securities analyst Lloyd Walmsley suggested that Meta’s Muse introduction might reignite investor concerns regarding Google’s Gemini AI capabilities and the potential impact of AI agents on conventional search engine business models.

ARK’s divestment of Alphabet shares represents a continuation of a multi-week trend. Wednesday’s transaction extended this pattern rather than representing an isolated strategic decision.

Biotech Portfolio Expansion

The investment firm also strengthened its biotech holdings throughout the trading day. ARK acquired 271,159 Beam Therapeutics shares for approximately $7.3 million. Beam’s stock declined 6.17% to $25.18 following the company’s release of interim results from a Phase 1/2 clinical study evaluating BEAM-302, an investigational therapy for alpha-1 antitrypsin deficiency.

ARK purchased 47,113 CRISPR Therapeutics shares valued at roughly $2.6 million. CRISPR’s stock price decreased 2.43% to $53.45 during the session.

Additionally, the firm acquired 204,206 Intellia Therapeutics shares for about $2.6 million. Intellia’s stock fell 4.16% to $12.21.

The Food and Drug Administration recently granted Priority Review status to Intellia’s lonvo-z application. The regulatory agency’s decision is anticipated by March 10, 2027. Upon approval, lonvo-z would represent the inaugural single-administration therapy for hereditary angioedema utilizing in vivo CRISPR-based gene modification technology.

Among ARK’s sales activity, the firm decreased its Tempus AI holdings by 22,767 shares, representing approximately $1.5 million in value. Tempus stock declined 4.68% during the session. ARK has systematically reduced its Tempus position over multiple consecutive trading periods.

ARK’s September 9 portfolio adjustments demonstrate a strategic reallocation from Alphabet toward Meta and biotechnology companies, capitalizing on price corrections while reducing exposure to positions experiencing downward momentum.

✨ Limited Time Offer